Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Candel TherapeuticsCADL -1.22%21 EV-to-OCF is -14.91 as of Sep. 01, 2026. GuruFocus rates CADL with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Candel Therapeutics ranks better than 77.41% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Candel Therapeutics's Enterprise Value is $835.43 Mil.
Candel Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-56.02 Mil. Therefore, Candel Therapeutics's EV-to-OCF for today is -14.91.
The historical rank and industry rank for Candel Therapeutics's EV-to-OCF or its related term are showing as below:
CADL'
s EV-to-OCF Range Over the Past 10 Years
Min: -16.43 Med: -3.67 Max: 0.35
Current: -14.91
During the past 7 years, the highest EV-to-OCF of Candel Therapeutics was 0.35. The lowest was -16.43. And the median was -3.67.
CADL's EV-to-OCF is ranked better than 77.41% of 1408
companies
in the Biotechnology industry
Industry Median: -3.685
vs CADL: -14.91
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Candel Therapeutics's PE Ratio (TTM) for today is calculated as:
Candel Therapeutics's share price for today is $12.905.
Candel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Candel Therapeutics EV-to-OCF Related Terms
Candel Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Candel Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Candel Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Candel Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Candel Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Candel Therapeutics's EV-to-OCF falls into.
Candel Therapeutics's current Enterprise Value is $835.43 Mil.
Candel Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics (CADL) has a EV-to-OCF of -14.91 as of Sep. 01, 2026. According to the industry distribution chart, Candel Therapeutics ranks #318 out of 1408 companies in the Biotechnology industry, placing it in the top 22.6%.
Is Candel Therapeutics' EV-to-OCF too high?
Candel Therapeutics' current EV-to-OCF is -14.91. Based on the distribution chart, Candel Therapeutics ranks #318 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Candel Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' EV-to-OCF compare to ABUS and WVE?
According to the Biotechnology industry distribution chart, Candel Therapeutics ranks #318 out of 1408 companies for EV-to-OCF. This places Candel Therapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Candel Therapeutics's current EV-to-OCF is -14.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current EV-to-OCF of -14.91. The current EV-to-OCF is -14.91. Candel Therapeutics' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current EV-to-OCF is -14.91 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
21GF Score
Get the complete analysis for CADL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CADL has been successfully added to your 
